ArticleCell death and differentiation2026
ACSL4-mediated astrocyte ferroptosis augments neuroinflammation and exacerbates NMOSD pathology.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comorbid mechanisms of neuroinflammation and astrocytic ferroptosis in neurological disorders: A vicious cycle (Review).Biomedical reports · 2026Review
- The Spatial Redox-Metalloptosis Axis in Liver Disease: A Hypothesis on Regional Susceptibility to Ferroptosis and Cuproptosis.Antioxidants (Basel, Switzerland) · 2026Review
- Cognitive impairment after cerebral ischemia-reperfusion injury: a neuroecosystem perspective.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is recognized as a form of astrocytopathy; however, the mechanisms underlying aquaporin (AQP)4-IgG-induced astrocytic dysfunction remain to be fully elucidated. Here, single-nucleus RNA sequencing revealed that astrocytic ferroptosis is observed in mouse models of NMOSD, accompanied by expression alterations of multiple ferroptosis regulators. The activation of ferroptosis in astrocytes was further confirmed in in vitro NMOSD models through increased intracellular Fe²⁺ levels, lipid peroxidation, malondialdehyde, and lactate dehydrogenase levels, alongside reduced glutathione levels. Moreover, a remarkable increase in inflammatory reactive astrocytes was observed both in vivo and in vitro during NMOSD pathology. Notably, acyl-CoA synthetase long-chain family member 4 (ACSL4) upregulation in astrocytes was validated in NMOSD models. AQP4-IgG-induced ACSL4 upregulation was reversed by early growth response 1 (Egr1) siRNA. Suppressing ACSL4 expression mitigated astrocytic ferroptosis, reduced reactive astrocytes, attenuated demyelination, and ultimately improved NMOSD prognosis in mice. These findings demonstrate that ACSL4 mediates astrocytic ferroptosis, thereby contributing to NMOSD progression. Targeting ACSL4 may represent a promising astrocyte-directed therapeutic strategy for NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.